Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Allegra · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Fexofenadine Tablets 180 mg |
| 2 | ACTIVE_COMPARATOR | Allegra® Tablets 180 mg |
| Name | Type | Description |
|---|---|---|
| Fexofenadine Tablets 180 mg | DRUG | 180mg, single dose fed |
| Allegra® Tablets 180 mg | DRUG | 180mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening...
Allegra is a small molecule drug being developed by Viatris Inc. (VTRS). It is currently in Phase 1 clinical development. The drug is being studied in healthy volunteers for research purposes, with two completed Phase 1 trials involving a total of 96 participants.
Allegra is being studied in healthy volunteers for research purposes. It is currently in Phase 1 clinical development, and the completed trials were conducted in the United States with participants aged 18 years and older. The drug is not yet approved for any specific medical condition.
Allegra is being developed by Viatris Inc., a company traded on the stock exchange under the ticker VTRS. The drug is currently in Phase 1 clinical development, with two completed trials in healthy volunteers.
Allegra is in Phase 1 clinical development. It is an investigational drug, meaning it is still being studied and has not been approved for medical use. Two Phase 1 trials have been completed, both involving healthy volunteers.
Allegra has been studied in two completed Phase 1 clinical trials: NCT00647985, a food study of fexofenadine tablets 180 mg and Allegra tablets 180 mg with 28 participants, and NCT00649376, a fasting study with 68 participants. Both trials were conducted in the United States with healthy volunteers.
Allegra is being studied in comparison with fexofenadine tablets in clinical trials. The trials are designed to evaluate the effects of Allegra tablets 180 mg against fexofenadine tablets 180 mg under food and fasting conditions. The drug is currently in Phase 1 development.